Transactions include an investment of up to US$5 million in PsyLabs and an approximately US$9 million value-matched share exchange

交易包括对PsyLabs高达500万美元的投资，以及价值约900万美元的等额换股。

Highlights

亮点

The Company is actively advancing plans for a potential ibogaine clinical trial in Texas for Opioid Use Disorder (OUD).

该公司正在积极推进在德克萨斯州开展针对阿片类药物使用障碍（OUD）的伊波加因潜在临床试验的计划。

Texas Ibogaine Research Corporation (TIRC), a dedicated U.S. subsidiary of Psyence BioMed, has been established for its planned ibogaine development activities in the US.

德克萨斯伊博格碱研究公司（TIRC）是Psyence BioMed在美国设立的全资子公司，旨在开展其计划中的伊博格碱开发活动。

Psyence BioMed has agreed to invest up to US$5 million in PsyLabs, of which US$2.4 million has been committed, to support scientific development and pharmaceutical-grade manufacturing capabilities relevant to the planned U.S. program.

Psyence BioMed 已同意向 PsyLabs 投资高达 500 万美元，其中 240 万美元已承诺到位，以支持与计划中的美国项目相关的科学研究及制药级生产能力建设。

Psyence BioMed and PsyLabs have agreed to a value-matched share exchange with a transaction value of approximately US$9 million on each side.

Psyence BioMed 与 PsyLabs 已达成等额换股协议，双方交易价值均约为 900 万美元。

NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company developing nature-derived neuroplastogen therapeutics, today announced that it has agreed to make a cash investment of up to US$5 million in Psyence Labs Ltd.

纽约，2026年9月23日（环球新闻社）——开发源自自然的神经可塑性治疗药物的生物制药公司Psyence Biomedical Ltd.（纳斯达克股票代码：PBM）（以下简称“Psyence BioMed”或“公司”）今日宣布，已同意向Psyence Labs Ltd.进行最高达500万美元的现金投资。

(“PsyLabs”), together with a value-matched share exchange between the two companies. The transactions are intended to support the scientific, manufacturing and development capabilities required for Psyence BioMed’s planned U.S. ibogaine program..

（“PsyLabs”），以及两家公司之间价值相等的股份交换。这些交易旨在支持 Psyence BioMed 计划中的美国伊波加因项目所需的科研、生产和开发能力。

TIRC, registered and headquartered in Texas, has been established to provide a dedicated corporate structure through which the Company can coordinate its planned U.S. regulatory, clinical and development activities involving pharmaceutical-grade ibogaine.

TIRC 在德克萨斯州注册并设立总部，其成立旨在提供一个专用的公司架构，以便本公司协调其涉及药用级伊波加因的美国监管、临床及开发活动。

The Company is currently evaluating the feasibility and design of a potential ibogaine clinical trial in Texas. Any clinical program would be subject to protocol development, regulatory review and authorization, institutional approvals, funding, site selection and other customary requirements.

本公司目前正在评估在德克萨斯州开展潜在伊博加因临床试验的可行性和设计。任何临床项目均需遵循方案开发、监管审查与授权、机构批准、资金落实、研究中心选择以及其他常规要求。

Texas has emerged as an important state for publicly supported ibogaine research. Psyence BioMed believes that establishing a dedicated presence in the state positions the Company to participate in this developing research environment while building the regulatory and clinical infrastructure required for a potential U.S.

德克萨斯州已成为获得公共支持的伊波加因研究的重要基地。Psyence BioMed 认为，在该州建立专门的布局将使公司能够参与这一不断发展的研究环境，同时为潜在的美国市场建设所需的监管和临床基础设施。

development program..

开发计划

Strategic Investment and Share Exchange

战略投资与股份置换

To support its planned development activities, Psyence BioMed has agreed to invest up to US$5 million in PsyLabs. The investment is intended to fund scientific work and the continued development of pharmaceutical-grade ibogaine manufacturing capabilities relevant to Psyence BioMed’s U.S. program. Psyence BioMed has irrevocably committed to subscribe for US$2.4 million (936 PsyLabs ordinary shares at US$2,564 per share, based on a pre-money equity valuation of PsyLabs of US$54 million) under its pro rata pre-emption entitlement in PsyLabs’ current financing round.

为支持其计划中的开发活动，Psyence BioMed已同意向PsyLabs投资最高500万美元。该投资旨在资助科学研究工作，并持续开发与Psyence BioMed美国项目相关的制药级伊波加因生产能力。根据其在PsyLabs当前融资轮次中按比例享有的优先认购权，Psyence BioMed已不可撤销地承诺认购240万美元（按PsyLabs投前股权估值5,400万美元计算，每股价格为2,564美元，共计936股PsyLabs普通股）。

The balance of up to US$2.6 million is a backstop commitment to subscribe for shares in that financing round not taken up by other PsyLabs shareholders, in up to two tranches of up to US$1.3 million each, payable upon certain milestones being achieved and other customary conditions. If the milestone tranches have not been called and completed by December 31, 2026, Psyence BioMed’s obligation to fund them will lapse..

高达260万美元的余额是一项后备承诺，用于认购该轮融资中其他PsyLabs股东未认购的股份，分最多两批进行，每批金额不超过130万美元，在实现某些里程碑及满足其他常规条件时支付。如果截至2026年12月31日尚未调用并完成这些里程碑批次，Psyence BioMed的资金提供义务将失效。

In addition to the abovementioned investment, the Company and PsyLabs have also agreed to a reciprocal share-for-share exchange, with each component valued at approximately US$9 million, subject to applicable corporate and regulatory approvals, required Nasdaq notifications and other customary closing conditions.

除上述投资外，公司与PsyLabs还达成了双向换股协议，各方对价约为900万美元，该交易须获得适用的公司及监管批准、履行所需的纳斯达克通知义务并满足其他惯常的交割条件。

The share exchange agreement may be terminated by any party if closing has not occurred by November 30, 2026. Under the agreed terms:.

若截至2026年11月30日尚未完成交割，任何一方均可终止股份交换协议。根据约定条款：

Psyence BioMed will issue 1,497,500 common shares to PsyLabs, representing approximately US$8.99 million in transaction value based on a deemed issue price of US$6.00 per PBM share; and

Psyence BioMed 将向 PsyLabs 发行 1,497,500 股普通股，按每股 PBM 股票 6.00 美元的视同发行价计算，交易价值约为 899 万美元；以及

PsyLabs will issue 3,473 ordinary shares to Psyence BioMed, representing an equivalent transaction value of approximately US$8.99 million based on an implied equity valuation of PsyLabs of US$60 million derived from an independent third-party valuation.

PsyLabs 将向 Psyence BioMed 发行 3,473 股普通股，相当于约 899 万美元的交易价值，该估值基于独立第三方评估得出的 PsyLabs 6000 万美元的隐含股权估值。

Psyence BioMed is making the cash investment, and will hold the PsyLabs shares to be issued under the share exchange, through its wholly-owned subsidiary, Psyence Biomed II Corp. The share exchange increases each company’s ownership interest in the other. Immediately prior to the transactions, PsyLabs held approximately 30.22% of Psyence BioMed’s issued and outstanding common shares, and Psyence BioMed held approximately 29.17% of PsyLabs’ issued and outstanding shares.

Psyence BioMed 正在进行现金投资，并将通过其全资子公司 Psyence Biomed II Corp. 持有在股份交换中发行的 PsyLabs 股份。此次股份交换增加了两家公司在彼此中的所有权权益。在交易完成前，PsyLabs 持有 Psyence BioMed 已发行和流通普通股的约 30.22%，而 Psyence BioMed 持有 PsyLabs 已发行和流通股份的约 29.17%。

Immediately following completion of the share exchange and the committed portion of the cash investment, PsyLabs will hold approximately 49.89% of Psyence BioMed’s issued and outstanding common shares, and Psyence BioMed will hold approximately 41.13% of PsyLabs’ issued and outstanding shares. The cash investment and the share exchange are related-party transactions.

在股份交换及承诺的现金投资部分完成后，PsyLabs将持有Psyence BioMed已发行及流通在外的普通股约49.89%，而Psyence BioMed将持有PsyLabs已发行及流通在外的股份约41.13%。该现金投资及股份交换构成关联方交易。

Psyence BioMed believes the transactions will more closely align its clinical and regulatory development activities with PsyLabs’ pharmaceutical-grade manufacturing and supply capabilities..

Psyence BioMed 认为，这些交易将使其临床和监管开发活动与 PsyLabs 的制药级生产和供应能力更加紧密地协同一致。

“Access to pharmaceutical-grade ibogaine is fundamental to the U.S. program we are planning,” said Jody Aufrichtig, Chief Executive Officer of Psyence BioMed and TIRC. “Our investment in PsyLabs, together with the share exchange, is intended to align Psyence BioMed more closely with the manufacturing and supply capabilities we believe a regulated clinical program will require, while TIRC provides the dedicated U.S.

“获得制药级伊波加因是我们正在规划的美国项目的基础，”Psyence BioMed 和 TIRC 的首席执行官乔迪·奥弗里希特表示。“我们对 PsyLabs 的投资，连同股份交换，旨在使 Psyence BioMed 与我们认为受监管的临床项目所需的制造和供应能力更紧密地对齐，而 TIRC 则提供专门的美国

structure through which we intend to advance that program. Our objective is to advance this program responsibly, supported by rigorous clinical research and pharmaceutical-grade manufacturing.”.

我们将通过该架构推进该项目。我们的目标是在严格的临床研究和制药级生产的支持下，负责任地推进该项目。”

“TIRC is intended to bring greater coordination to the regulatory, clinical and operational components of our planned U.S. program,” said Dr. John Thorne, Project Lead of TIRC. “We are now evaluating the requirements for a potential clinical trial, including the development plan, regulatory pathway, manufacturing documentation and necessary clinical capabilities.”.

“TIRC旨在为我们计划中的美国项目在监管、临床和运营方面带来更高效的协调，”TIRC项目负责人John Thorne博士表示。“我们目前正在评估潜在临床试验的各项要求，包括开发计划、监管路径、生产文件以及必要的临床能力。”

“PsyLabs has invested significant time and expertise in developing a controlled supply and manufacturing platform for pharmaceutical grade ibogaine,” said Tony Budden, Chief Executive Officer of PsyLabs. “This investment is intended to allow us to further develop that capability in support of Psyence BioMed’s planned U.S.

PsyLabs 首席执行官托尼·巴登表示：“PsyLabs 投入了大量时间和专业知识，开发用于制药级伊波加因的受控供应和生产平台。”“这项投资旨在使我们能够进一步发展这一能力，以支持 Psyence BioMed 计划在美国开展的”

program and the quality requirements associated with regulated clinical research.”.

计划以及与受监管临床研究相关的质量要求。”

TIRC will initially draw upon Psyence BioMed’s existing legal, administrative and financial resources, with corporate oversight that includes Chief Financial Officer Warwick Corden-Lloyd and the Company’s in-house legal function.

TIRC 将初步依托 Psyence BioMed 现有的法律、行政和财务资源，并由包括首席财务官 Warwick Corden-Lloyd 以及公司内部法律职能部门在内的企业监督机制进行监管。

ABOUT

关于

PSYENCE

伪科学

BIOMED

生物医学

Psyence Biomedical Ltd. (Nasdaq: PBM) is a Nasdaq-listed company with its subsidiary, Texas Ibogaine Research Corporation, headquartered in Texas. It is one of the few multi-asset, vertically integrated biopharmaceutical companies specializing in neuroplastogen-based therapeutics and the manufacture of pharmaceutical-grade drug candidates.

Psyence Biomedical Ltd.（纳斯达克股票代码：PBM）是一家在纳斯达克上市的公司，其子公司德克萨斯伊波加因研究公司（Texas Ibogaine Research Corporation）总部位于德克萨斯州。该公司是为数不多的多资产、垂直整合的生物制药企业之一，专注于基于神经塑性原的疗法以及药物级候选药物的生产。

It is the first life sciences biotechnology company focused on developing nature-derived, non-synthetic psilocybin and ibogaine-based neuroplastogen medicine to be listed on Nasdaq. The Company is dedicated to addressing unmet mental health needs and is committed to an evidence-based approach to developing safe, effective and FDA-approved nature-derived neuroplastogen treatments across a range of mental health disorders..

这是首家在纳斯达克上市的生命科学生物技术公司，专注于开发源自自然的、非合成的基于裸盖菇素和伊波加因的神经可塑性药物。该公司致力于满足尚未被充分关注的心理健康需求，并坚持以循证方法开发安全、有效且获美国食品药品监督管理局（FDA）批准的源自自然的神经可塑性疗法，用于治疗多种心理健康障碍。

ABOUT

关于

PSYLABS

PSYLABS

PsyLabs is a neuroplastogen active pharmaceutical ingredient development company, federally licensed in its operating jurisdiction to cultivate, extract and export psilocybin mushrooms and other neuroplastogen compounds, including psilocybin, psilocin, mescaline, ibogaine and dimethyltryptamine, to lawful medical and research markets.

PsyLabs 是一家神经可塑性药物活性成分开发公司，在其运营辖区获得联邦许可，可向合法医疗和研究市场种植、提取并出口裸盖菇及其他神经可塑性化合物（包括裸盖菇素、裸盖菇辛、麦司卡林、伊波加因和二甲基色胺）。

PsyLabs operates from an ISO 22000 and GMP-compliant facility, with a focus on natural compound purification, regulatory support and global distribution. .

PsyLabs 在符合 ISO 22000 和 GMP 标准的设施中运营，专注于天然化合物纯化、法规支持及全球分销。

www.psylabs.life

www.psylabs.life

CONTACTS

联系人

Psyence Biomedical Ltd. ·

Psyence 生物医学有限公司 ·

ir@psyencebiomed.com

ir@psyencebiomed.com

·

·

media@psyencebiomed.com

media@psyencebiomed.com

·

·

info@psyencebiomed.com

info@psyencebiomed.com

· +1 416-477-1708

· +1 416-477-1708

Investor contact: Michael Kydd, Investor Relations Advisor —

投资者联系人：Michael Kydd，投资者关系顾问 —

michael@psyencebiomed.com

michael@psyencebiomed.com

FORWARD-LOOKING

前瞻性

STATEMENTS

声明

This communication contains forward-looking statements within the meaning of applicable securities laws, including the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding the proposed share exchange and the proposed US$5 million cash investment by Psyence BioMed into PsyLabs and their anticipated terms, pricing, timing, completion and effects; the application of the proceeds of that investment; the resulting shareholdings of Psyence BioMed and PsyLabs in one another; the formation, capitalization, funding and intended role of TIRC; the Company's ability to secure pharmaceutical-grade drug substance and the regulatory documentation required to support a United States program; the evaluation, funding, design, timing and conduct of any clinical trial in Texas; the Company's ability to obtain and maintain required registrations, permits, quotas and licenses; its ability to participate in federal or state ibogaine programs; and its expected role in future research, development and commercialization activities relating to ibogaine.

本通讯包含适用证券法律（包括美国1995年《私人证券诉讼改革法》）所定义的前瞻性陈述，包括有关拟议的股份交换以及Psyence BioMed向PsyLabs进行的拟议500万美元现金投资及其预期条款、定价、时间安排、完成情况及影响的陈述；该投资收益的用途；Psyence BioMed与PsyLabs相互持有的 resultant 股权；TIRC的成立、资本化、资金安排及预期角色；公司确保获得药品级药物活性成分及支持美国项目所需的监管文件的能力；在德克萨斯州进行的任何临床试验的评估、资金安排、设计、时间安排及实施；公司获取并维持所需注册、许可、配额和许可证的能力；其参与联邦或州级伊波加因项目的能力；以及其在未来与伊波加因相关的研究、开发和商业化活动中的预期角色。

Such statements may be identified by words including will, expects, intends, plans, anticipates, believes, estimates and similar expressions..

此类陈述可通过包括“将”、“预期”、“打算”、“计划”、“预计”、“相信”、“估计”及类似表述在内的词语加以识别。

These statements rest on assumptions regarding government policy, continued interest in regulated neuroplastogen research, the availability of lawful development pathways, and the Company's ability to maintain licenses, permits, supply arrangements and third-party relationships. Risks and uncertainties that could cause actual results to differ materially include: that the investments and share exchange or the corporate arrangements described are not completed on the terms or timetable expected, or at all; that required board, shareholder, regulatory or stock exchange approvals are not obtained; dilution to existing shareholders and the concentration of ownership resulting from the share exchange; that the share exchange and the cash investment are transactions between related parties, and that the terms agreed may differ from those that would be agreed between unrelated parties; that the US$6.00 per PBM share price at which PBM shares are issued under the exchange may not be indicative of the value at which those shares can be realized; that the valuations used to price the exchange and the cash investment are not indicative of realizable value; changes in law, regulation or enforcement priorities in the United States, Southern Africa or elsewhere; the continuing status of ibogaine as a controlled substance; clinical, regulatory and approval risk; competition and market adoption risk; financing risk; and the Company's ability to maintain compliance with Nasdaq continued listing standards.

这些陈述基于以下假设：政府政策、对受监管的神经可塑性生成物（neuroplastogen）研究的持续兴趣、合法开发途径的可用性，以及本公司维持许可证、许可、供应安排和第三方关系的能力。可能导致实际结果与预期产生重大差异的风险和不确定性包括：所述投资、股份交换或公司安排未能按预期的条款或时间表完成，或根本未完成；未能获得所需的董事会、股东、监管机构或证券交易所批准；现有股东因股份交换而面临的股权稀释及所有权集中；股份交换和现金投资属于关联方交易，其商定条款可能不同于非关联方之间商定的条款；根据交换协议发行PBM股份所采用的每股6.00美元价格，可能不能反映这些股份可实现的价值；用于对股份交换和现金投资进行定价的估值可能不能反映可实现价值；美国、南部非洲或其他地区的法律、法规或执法重点发生变化；伊波加因（ibogaine）作为受管制物质的持续状态；临床、监管和审批风险；竞争和市场采纳风险；融资风险；以及本公司维持符合纳斯达克持续上市标准的能力。

This list is not exhaustive. These risks should be considered together with the risk factors described in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the fiscal year ended March 31, 2026 and in the Company’s other filings with the U.S. Securities and Exch.

该列表并非详尽无遗。在评估这些风险时，应结合公司截至2026年3月31日财政年度的20-F表格年度报告中“风险因素”部分所述的风险因素，以及公司向美国证券交易委员会提交的其他文件中的相关描述一并考虑。

The Company makes no medical, treatment or health benefit claims regarding its proposed products. The U.S. Food and Drug Administration, Health Canada and other regulatory authorities have not approved ibogaine or the Company’s other neuroplastogen compounds for therapeutic use, and their safety and efficacy have not been established through authorized clinical research.

本公司不就其拟议产品作出任何医疗、治疗或健康效益方面的声明。美国食品药品监督管理局、加拿大卫生部及其他监管机构尚未批准伊波加因或本公司的其他神经可塑性化合物用于治疗用途，且其安全性和有效性尚未通过授权的临床研究得到证实。

Rigorous scientific research and clinical trials are required. Any references to ibogaine stock, inventory or doses are the Company's best estimates only. References to GMP-compliant mean production in a facility designed, operated and controlled in accordance with applicable Good Manufacturing Practice standards, and do not themselves constitute a representation of formal certification or approval by any regulatory authority unless expressly stated.

需要进行严格的科学研究和临床试验。任何对伊波加因库存、存货或剂量的提及仅为公司的最佳估计。提及符合药品生产质量管理规范（GMP）是指在与适用的良好生产规范标准相符的设计、运营和控制的设施中进行生产，除非明确声明，否则其本身并不构成由任何监管机构颁发的正式认证或批准的陈述。

References to a planned clinical trial describe an activity under evaluation only; no trial has been commenced, and no regulatory application in respect of it has been filed or accepted. This communication is not an offer to sell or a solicitation of an offer to buy any securities..

对计划中的临床试验的提及仅描述处于评估阶段的活动；尚未启动任何试验，也未提交或获受理任何相关的监管申请。本通讯不构成出售任何证券的要约，也不构成购买任何证券要约的招揽。